Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is poised for success with its Breakthrough Therapy Designation, promising drug cadisegliatin, and potential success in reducing HbA1c and hypoglycemia in phase 3 trials. With the FDA prioritizing a cure or treatment for type 1 diabetes and a projected price target of $49, the stock has strong potential for growth. The company's focus on raising funds and pursuing other potential therapies, such as dorzagliatin, showcases its dedication to finding effective treatments for chronic diseases.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company with a primary focus on developing therapies for diabetes. However, the recent insulin withdrawal study raises concerns about potential side effects and indicates that the drug may not be as effective as initially anticipated. Additionally, the company has several non-core programs which may offer partnering optionality, but are not included in their current valuation. The company also faces some potential risks, including regulatory, commercial, and competitive risks. This negative outlook is further compounded by a lack of current financial success, as shown by the absence of significant revenues and earnings.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Jun 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.